Enhanced efficacy and specificity of epithelial ovarian carcinogenesis by embedding a DMBA-coated cloth strip in the ovary of rat
- Yiping Huang†1, 2,
- Wei Jiang†1, 2,
- Yisheng Wang1, 2,
- Yufang Zheng3,
- Qing Cong1, 2 and
- Congjian Xu1, 2, 4Email author
© Huang et al.; licensee BioMed Central Ltd. 2012
Received: 3 July 2012
Accepted: 21 August 2012
Published: 3 September 2012
Ovarian cancer is predominant of epithelial cell origin and often present at an advanced stage with poor prognosis. Most animal models of ovarian carcinoma yield thecal/granulose cell tumors, rather than adenocarcinomas. The best reported induction rate of adenocarcinoma in rats is 10-45% by an ovarian implantation of 7, 12-dimethylbenz[a]anthracene (DMBA) coated silk suture. We provided an improved procedure to construct the model by the ovarian implantation of DMBA-coated cloth strip.
A sterile suture (as S group) or a piece of cloth strip (as CS group) was soaked in DMBA before ovarian implantation in Wistar rats. Tumor size, incidence rate and pathological type were analyzed.
Ovarian tumors in rats of CS group were first noted at 16 wk post implantation and reached a cumulative incidence of 75% (96/128) at 32 wk, while the tumor incidence rate in S group at 32 wk was only 46.25% (37/80). The tumor size in CS group (3.63 ± 0.89 cm) was larger than that of S group (2.44 ± 1.89 cm) (P < 0.05). In CS group, there were only two types of tumor formed: adenocarcinoma (90/96) and sarcoma (6/96). While in S group, there were different types, including adenocarcinoma (21/37), squamous carcinoma (3/37), granulosa cell tumor (3/37), sarcoma (4/37), undifferentiated carcinoma with no adeno character (2/37), benign ovarian tumor (2/37), and malignant teratoma (1/37).
The model in our study yields much higher incidence and specificity of epithelial derived tumors and showed histological similarities to human ovarian cancers, which would be more suitable for therapeutic research.
KeywordsOvarian cancer Carcinogenesis DMBA Animal model Rat
Epithelial ovarian cancer is a leading cause of female cancer mortality in the world . In contrast to other women-specific cancers, like breast and uterine carcinomas, where death rates have fallen in recent years, ovarian cancer cure rates have remained relatively unchanged over the past two decades . Ovarian adenocarcinomas account for 85-90% of all cancers of the ovary . Effective detection and treatment of ovarian cancer remains a significant clinical challenge. The exactly initiating cell population for epithelial ovarian carcinoma (EOC) remains to be defined. Different evidences have suggested that EOC originate from the ovarian surface epithelium, inclusion cysts lined [4–7] or alternatively, the fallopian tube epithelium  or components of the secondary Müllerian system, including the epithelial cells of the rete ovarii, paraovarian/ paratubal cysts, endosalpingiosis, endometriosis or endomucinosis [9–13].
Because the results of ovarian carcinoma treatment are still far from optimal, animal models are still needed to study the human EOC. Even though spontaneous ovarian tumors in rodents have been reported , the paucity of these cases precludes their use in modeling ovarian cancer. Therefore, much effort has been put into developing relevant animal models for ovarian cancers. One such model involves the use of the carcinogen, 7, 12-dimethylbenz[a]anthracene (DMBA), a polycyclic aromatic hydrocarbon that induces carcinogenic mutations by forming DNA adducts . Incidence of ovarian adenocarcinoma induction by DMBA varies between 10 to 45% [16, 17], which probably due to the strain difference of rat employed, the chemical form of the DMBA utilized and the route of drug administrated in those studies.
Direct implantation of carcinogen appears to be critical as a single intragastric instillation or intravenous injection of DMBA in mice yields a comparable total tumor incidence, even though virtually most of the tumor exhibited a stromal tumor histology . The traditional drug-containing silk suture implants would inevitably damage the stroma of ovary, leading to the diverse of pathological types of ovarian tumors in addition to epithelial tumors, such as sarcoma, granular cell tumor, etc. We report here that 75% tumor incidence at the end of 32 wk and 93.75% (90/96) of all tumors diagnosed as adenocarcinoma by implanting a piece of cloth strip soaked with high purity DMBA onto the surface of Wistar rat ovary. To our knowledge, this is the first report to use a cloth strip embedding to the surface of ovary to induce ovarian cancer.
Material and methods
Tumor induction procedures and evaluation
This study was performed in strict accordance with the recommendations in the Guide for the Care and Use of Laboratory Animals of the National Science and Technology Committee. All protocols were approved by the Biomedical Research Ethics Committee of Shanghai Institute for Biological Science of Chinese Academy of Sciences. Every effort was made to minimize suffering.
Preparation and analysis of tissues and histology
Histologic subtyping of DMBA-induced ovarian carcinomas in rats
An adenocarcinoma characterized by a pattern of papillae with cellular budding
An adenocarcinoma composed of simple or pseudostratified epithelial cells, or occasionally with squamous differentiation
clear cell carcinoma
An adenocarcinoma mainly composed of hobnail cells
An adenocarcinoma composed of endocervical-like and intestinal type cells
Granulosa cell tumor
A neoplasm composed of granulosa cells
A carcinoma composed of squamous epithelial cells
A neoplasm composed of malignant nonepithelial cells
Teratoma with any malignant contents
A carcinoma with no Specifically differentiated cells
Benign ovarian tumor
All tumors without malignant characters
Paraffin-embedded sections for immunohistochemistry were dewaxed, rehydrated and processed for antigen unmasking by heating to near boiling in citrate buffer (0.01 M, pH 6.0, 30 min) in a microwave oven, then allowed to cool for 20 min. Following this and all subsequent incubations except for the blocking serum, the slides were washed in phosphate-buffered saline (PBS, 3 × 5 min). Endogenous peroxidase activity was blocked by hydrogen peroxide incubation (0.3% in methanol) for 5 min. After incubation for 30 min in blocking serum (diluted 1:50 in PBS) appropriate to each secondary antibody, the slides were incubated with primary antibody at 4°C overnight (Primary antibodies were omitted as negative controls.) The primary antibodies used were as follows: polyclonal anti-rat Pan-CK (Santa Cruz Biotechnology, Santa Cruz, CA, USA), polyclonal anti-rat inhibin A (Santa Cruz Biotechnology, Santa Cruz, CA, USA),and polyclonal anti-rat vimentin (Abcam, ). Detection of primary antibody proceeded with the binding of biotinylated secondary antibody (diluted 1:200 for 10 min at room temperature) followed by avidin-biotin peroxidase complex (Vectastain Elite, Vector Laboratories, Burlingame, CA) and diaminobenzidine (DAB) chromagen substrate. Dark brown structures indicated positive immunostaining.
The comparison of distribution of variables between two groups was made using the t-test (SPSS Statistics v13.0, Chicago, IL), with significance set at a P value of less than 0.05.
Incidence of ovarian cancers
Morphologic features of ovaries after DMBA treatment
Histological features of induced tumor
Immunohistochemistry of induced tumors
In past, the DMBA treatment does not always successfully produce ovarian carcinoma with the rate of incidence at approximately 50% . To date, a lot of reports available on overall DMBA-induced carcinoma in mice or rat have shown reproducible ovarian neoplasms with different delivery methods (gavage versus coated suture), dosage, length of exposure, and length of time before collection of tissues. In one study, C57BL6 mice received daily doses of DMBA by gavage for 3 wk; 71% of animals developed granulosa cell tumors after one year . In another study, mice of a C57BL6; FVB/NCr background received a weekly dose of DMBA by gavage for 6 wk; 6 months after treatment, 27.3% (12/44) of mice developed ovarian neoplasms, of which 58% were granulosa cell tumors . More recently, a study assessing the incidence of cancers in mice with a P5 3 (p53Ala135Val/wt) mutation found that 80% of mice that received implants of DMBA-coated suture into their ovaries developed ovarian tumors, of which 50% were adenocarcinomas when evaluated 3 months after implantation .
Generally, traditional immunohistochemical markers used for the distinction of epithelial, stromal and granulosa ovarian tumor, such as CK, vimentin and inhibin A can be useful, and sometimes, they may show overlapping patterns of expression [23, 24]. For example, vimentin could be immunostained in mucinous tumor, serous tumor, and low-grade endometrioid tumor [25–27]; inhibin A could be strongly expressed in epithelial ovarian cancer and other types of ovarian malignancies [25, 26]. In our study, we determined the subtype of induced ovarian cancer by histologic observations in combination with immunohistochemistry. CK was expressed in the cancer cell of adenocarcinoma and normal ovarian surface epithelium but not in sarcoma and stromal. Although inhibin A was thought to be the specific marker of grunulosa cell, we detected it in the most of adenocarcinoma and some sarcoma cells in our induced tumors. This may due to some biological differences between the ovarian cancer of rat and human. Further investigations are required to address the discrepancies.
Compared with the ovaries of human beings, spontaneous development of epithelial neoplasms is rare in the ovaries of rodents [27, 28]. One postulated reason for such low incidence is that the rat ovary is completely enveloped by a membranous pouch, which protects the surface epithelium against the effects of local carcinogens . In our study, as shown in Figure 4, most of ovarian tumors induced in the embedded cloth strip group are adenocarcinoma and comfirmed by immunohistochemistry (Figure 6) while the silk suture group contained quite a lot of non-epithelial type tumors. The distinctly different outcome of two groups may due to the procedure during operation. In CS group, we maximally kept the inner part of ovaries uninjured by only dissecting their membranous pouch and let the surface cell exposed to drugs. While in S group, we inevitably injured the deep tissue of the ovaries when inserting the DMBA-coated suture by a needle to allow the drug penetrate into the tissues besides surface. Our results also provided further evidence that the origin of ovarian epithelial cancer derived from ovarian surface cell, and other types of cancer may originate from middle layer of ovary.
Intriguingly, the tumor size in our CS group had a lower standard deviation (S.D.) value than that of S group (0.89 vs. 1.89) (Figure 3). Thus, the cloth strip model generates a more homogeneous ovarian epithelial cancer model. It should provide a more suitable animal model for the research of ovarian cancer than any chemical-induced model reported previously.
In summary, the results of this study indicate that the DMBA cloth strip model in rat yields high incidence and specificity of epithelial derived tumors histologically similar to human EOC and should be suitable for testing preventive or therapeutic agents for EOC.
Epithelial ovarian carcinoma.
Financial support: National Natural Sciences Foundation of China (No. 30901588), National Natural Sciences Foundation of China (No. 81202052) and Guidance Research Programs of Science and Technology Commission Foundation of Shanghai (No. 114119a2300).
- Atkins CD: Neoadjuvant chemotherapy or primary surgery in advanced ovarian cancer. N Engl J Med 2010, 363: 2371–2372.PubMedGoogle Scholar
- Miller SM, Roussi P, Daly MB, Scarpato J: New strategies in ovarian cancer: uptake and experience of women at high risk of ovarian cancer who are considering risk-reducing salpingo-oophorectomy. Clin Cancer Res 2010, 16: 5094–5106. 10.1158/1078-0432.CCR-09-2953PubMed CentralPubMedView ArticleGoogle Scholar
- Landen CN, Birrer MJ, Sood AK: Early events in the pathogenesis of epithelial ovarian cancer. J Clin Oncol 2008, 26: 995–1005. 10.1200/JCO.2006.07.9970PubMedView ArticleGoogle Scholar
- Lengyel E: Ovarian cancer development and metastasis. Am J Pathol 2010, 177: 1053–1064. 10.2353/ajpath.2010.100105PubMed CentralPubMedView ArticleGoogle Scholar
- Murphy SK: Targeting ovarian cancer-initiating cells. Anticancer Agents Med Chem 2010, 10: 157–163.PubMedView ArticleGoogle Scholar
- Dyck HG, Hamilton TC, Godwin AK, Lynch HT, Maines-Bandiera S, Auersperg N: Autonomy of the epithelial phenotype in human ovarian surface epithelium: changes with neoplastic progression and with a family history of ovarian cancer. Int J Cancer 1996, 69: 429–436. 10.1002/(SICI)1097-0215(19961220)69:6<429::AID-IJC1>3.0.CO;2-6PubMedView ArticleGoogle Scholar
- Dietl J, Marzusch K: Ovarian surface epithelium and human ovarian cancer. Gynecol Obstet Invest 1993, 35: 129–135. 10.1159/000292682PubMedView ArticleGoogle Scholar
- Kurman RJ, Shih Ie M: The origin and pathogenesis of epithelial ovarian cancer: a proposed unifying theory. Am J Surg Pathol 2010, 34: 433–443. 10.1097/PAS.0b013e3181cf3d79PubMed CentralPubMedView ArticleGoogle Scholar
- Ahmed AA, Becker CM, Bast RC: The origin of ovarian cancer. BJOG 2012, 119: 134–136. 10.1111/j.1471-0528.2011.03149.xPubMedView ArticleGoogle Scholar
- Zavesky L, Jancarkova N, Kohoutova M: Ovarian cancer: origin and factors involved in carcinogenesis with potential use in diagnosis, treatment and prognosis of the disease. Neoplasma 2011, 58: 457–468. 10.4149/neo_2011_06_457PubMedView ArticleGoogle Scholar
- Kurman RJ, Shih Ie M: Molecular pathogenesis and extraovarian origin of epithelial ovarian cancer–shifting the paradigm. Hum Pathol 2011, 42: 918–931. 10.1016/j.humpath.2011.03.003PubMed CentralPubMedView ArticleGoogle Scholar
- Birrer MJ: The origin of ovarian cancer-is it getting clearer? N Engl J Med 2010, 363: 1574–1575. 10.1056/NEJMe1009527PubMedView ArticleGoogle Scholar
- Liu J, Yang G, Thompson-Lanza JA, Glassman A, Hayes K, Patterson A, Marquez RT, Auersperg N, Yu Y, Hahn WC, et al.: A genetically defined model for human ovarian cancer. Cancer Res 2004, 64: 1655–1663. 10.1158/0008-5472.CAN-03-3380PubMedView ArticleGoogle Scholar
- Gimeno MF, Gimeno AL: Studies on the ovarian motility of small laboratory rodents. Acta Physiol Lat Am 1975, 25: 227–228.PubMedGoogle Scholar
- Stewart SL, Querec TD, Ochman AR, Gruver BN, Bao R, Babb JS, Wong TS, Koutroukides T, Pinnola AD, Klein-Szanto A, et al.: Characterization of a carcinogenesis rat model of ovarian preneoplasia and neoplasia. Cancer Res 2004, 64: 8177–8183. 10.1158/0008-5472.CAN-04-1702PubMedView ArticleGoogle Scholar
- Hilfrich J: Comparative morphological studies on the carcinogenic effect of 7,12-dimethylbenz(A)anthracene (DMBA) in normal or intrasplenic ovarian tissue of C3H mice. Br J Cancer 1975, 32: 588–595. 10.1038/bjc.1975.265PubMed CentralPubMedView ArticleGoogle Scholar
- Crist KA, Zhang Z, You M, Gunning WT, Conran PB, Steele VE, Lubet RA: Characterization of rat ovarian adenocarcinomas developed in response to direct instillation of 7,12-dimethylbenz[a]anthracene (DMBA) coated suture. Carcinogenesis 2005, 26: 951–957.PubMedView ArticleGoogle Scholar
- Tunca JC, Erturk E, Bryan GT: Chemical induction of ovarian tumors in rats. Gynecol Oncol 1985, 21: 54–64. 10.1016/0090-8258(85)90232-XPubMedView ArticleGoogle Scholar
- Ting AY, Kimler BF, Fabian CJ, Petroff BK: Characterization of a preclinical model of simultaneous breast and ovarian cancer progression. Carcinogenesis 2007, 28: 130–135. 10.1093/carcin/bgl140PubMedView ArticleGoogle Scholar
- McDermott SP, Ranheim EA, Leatherberry VS, Khwaja SS, Klos KS, Alexander CM: Juvenile syndecan-1 null mice are protected from carcinogen-induced tumor development. Oncogene 2007, 26: 1407–1416. 10.1038/sj.onc.1209930PubMedView ArticleGoogle Scholar
- Hoyer PB, Davis JR, Bedrnicek JB, Marion SL, Christian PJ, Barton JK, Brewer MA: Ovarian neoplasm development by 7,12-dimethylbenz[a]anthracene (DMBA) in a chemically-induced rat model of ovarian failure. Gynecol Oncol 2009, 112: 610–615. 10.1016/j.ygyno.2008.12.013PubMed CentralPubMedView ArticleGoogle Scholar
- Wang Y, Zhang Z, Lu Y, Yao R, Jia D, Wen W, LaRegina M, Crist K, Lubet R, You M: Enhanced susceptibility to chemical induction of ovarian tumors in mice with a germ line p53 mutation. Mol Cancer Res 2008, 6: 99–109. 10.1158/1541-7786.MCR-07-0216PubMedView ArticleGoogle Scholar
- Jeschke U, Mylonas I, Kunert-Keil C, Stahn R, Scholz C, Janni W, Kuhn C, Schroder E, Mayr D, Friese K: Immunohistochemistry, glycosylation and immunosuppression of glycodelin in human ovarian cancer. Histochem Cell Biol 2009, 131: 283–295. 10.1007/s00418-008-0510-zPubMedView ArticleGoogle Scholar
- Heinrich JK, Bottcher-Luiz F, Andrade LL, Davidson S, Bonds L, Stephens J, Varella-Garcia M: HER-2 and cancer antigen 125 evaluation in ovarian borderline tumors by immunohistochemistry and fluorescence in situ hybridization. Int J Gynecol Cancer 2004, 14: 1078–1085. 10.1111/j.1048-891X.2004.14605.xPubMedView ArticleGoogle Scholar
- Robertson DM, Pruysers E, Jobling T: Inhibin as a diagnostic marker for ovarian cancer. Cancer Lett 2007, 249: 14–17. 10.1016/j.canlet.2006.12.017PubMedView ArticleGoogle Scholar
- Cooke I, O'Brien M, Charnock FM, Groome N, Ganesan TS: Inhibin as a marker for ovarian cancer. Br J Cancer 1995, 71: 1046–1050. 10.1038/bjc.1995.201PubMed CentralPubMedView ArticleGoogle Scholar
- Choi YS, Hoory T, Monie A, Wu A, Connolly D, Hung CF: Alpha-Galactosylceramide enhances the protective and therapeutic effects of tumor cell based vaccines for ovarian tumors. Vaccine 2008, 26: 5855–5863. 10.1016/j.vaccine.2008.08.027PubMed CentralPubMedView ArticleGoogle Scholar
- Godwin AK, Testa JR, Handel LM, Liu Z, Vanderveer LA, Tracey PA, Hamilton TC: Spontaneous transformation of rat ovarian surface epithelial cells: association with cytogenetic changes and implications of repeated ovulation in the etiology of ovarian cancer. J Natl Cancer Inst 1992, 84: 592–601. 10.1093/jnci/84.8.592PubMedView ArticleGoogle Scholar
- Chien JR, Aletti G, Bell DA, Keeney GL, Shridhar V, Hartmann LC: Molecular pathogenesis and therapeutic targets in epithelial ovarian cancer. J Cell Biochem 2007, 102: 1117–1129. 10.1002/jcb.21552PubMedView ArticleGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.